Minimum important difference for validated instruments in women with urge incontinence

Neurourology and Urodynamics

Volumn 30, Issue 7, 2011, Pages 1319-1324

  Dyer, Keisha Y ^a   Xu, Yan ^b   Brubaker, Linda ^c   Nygaard, Ingrid ^d   Markland, Alayne ^e   Rahn, David ^f   Chai, Toby C ^g   Stoddard, Ann ^b   Lukacz, Emily ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF MARYLAND   (United States)

Author keywords

MID; overactive bladder; urge incontinence

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; BEHAVIOR THERAPY; DISEASE SEVERITY; EFFECT SIZE; FEMALE; HUMAN; INSTRUMENT VALIDATION; MAJOR CLINICAL STUDY; MEASUREMENT ERROR; METHODOLOGY; MINIMUM IMPORTANT DIFFERENCE; MULTICENTER STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; URGE INCONTINENCE;

ADULT; AGED; BEHAVIOR THERAPY; CHOLINERGIC ANTAGONISTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHOMETRICS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE;

EID: 80052048600     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.21028     Document Type: Article

References (21)

1. Hartmann KE, McPheeters ML, Biller DH, et al. Treatment of overactive bladder in women. Evidence report/technology assessment no. 187. Rockville, MD: Agency for Healthcare Research and Quality; 2009. AHRQ publication no. 09-E017.
2. Irwin DE, Milsom I, Kopp Z, et al. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 2008; 53: 1029-37.
3. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: A comparative study. Urology 2004; 63: 461-5.
4. Coyne KS, Zhou Z, Thompson C, et al. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003; 92: 731-5. (Pubitemid 37475816)
5. Shumaker SA, Wyman JF, Uebersax J, et al. Health-related quality of life measures for women with urinary incontinence: The Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Qual Life Res 1994; 3: 291-306. (Pubitemid 24358745)
6. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res 2002; 11: 563-74. (Pubitemid 34876130)
7. Matza LS, Thompson CL, Krasnow J, et al. Test-retest reliability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 2005; 24: 215-25. (Pubitemid 40617094)
8. Coyne KS, Matza LS, Thompson CL,. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 2005; 14: 849-55. (Pubitemid 40576869)
9. Coyne KS, Matza LS, Thompson CL, et al. Determining the importance of change in the OAB-q. J Urol 2006; 176: 627-32.
10. Van Kerrebroeck PEV, Kelleher CJ, Coyne KS, et al. Correlations among improvements in urgency urinary incontinence, health-related quality of life and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes 1009; 7: 13.
11. Barber MD, Spino C, Janz NK, et al. The minimum important differences for the urinary scales of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire. Am J Obstet Gynecol 2009; 200: 580.e1-7.
12. Barrett B, Brown R, Mundt M,. Comparison of anchor-based and distributional approaches in estimating important difference in common cold. Qual Life Res 2008; 17: 75-85.
13. Symonds T, Spino C, Sisson M, et al. Methods to determine the minimum important difference for a sexual event diary used by postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2006; 4: 1328-35. (Pubitemid 47337677)
14. Burgio KD, Kraus SR, Menefee S, et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: A randomized trial. Ann Intern Med 2008; 149: 161-9.
15. Cohen J,. Statistical power analysis for the behavioral sciences. New York: Academic Press Inc.; 1977.
16. Burgio KL, Goode PS, Richter HE, et al. Global rating of patient satisfaction and perception of improvement with treatment for urinary incontinence: Validation of three global patient ratings. Neurourol Urodynam 2006; 25: 411-7.
17. Ward MM, Marx AS, Barry NN,. Identification of clinically important changes in health status using receiver operating characteristic curves. J Clin Epidemiol 2000; 53: 279-84. (Pubitemid 30173247)
18. Wyrwich KW, Tierney WM, Wolinsky FD,. Using the standard error of measurement to identify important changes on the Asthma Quality of Life Questionnaire. Qual Life Res 2002; 11: 1-7. (Pubitemid 34293381)
19. Wyrwich KW, Nienaber NA, Tierney WM, et al. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999; 37: 469-78.
20. Revicki D, Hays RD, Cella C, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008; 61: 102-9.
21. Food and Drug Administration. Guidance for industry patient-related outcome measures: Use in medical product development to support labeling claims. "Planning for Clinical Trial Interpretation Using a Responder Definition" (Section IV.E), pp. 24-5.